Read Full Story Tozzer Library returned to an entirely rebuilt and redesigned space following two years in temporary quarters.The original Tozzer Library building was almost completely demolished and rebuilt and enlarged to reunite Harvard’s anthropological community for the first time in over 50 years. Tozzer is connected to the Peabody Museum, where some Anthropology Department offices continue to be housed, via a glass walkway.Visit the new Tozzer space at 21 Divinity Avenue.
Deliveries to India, which has a population of more than 1.3 billion, could begin in late 2020, RDIF said, adding this was subject to the completion of trials and Sputnik-V’s registration by regulatory authorities in India.Phase III trials, involving at least 40,000 people, are ongoing in Russia. Initial results are expected in October or November, RDIF head Kirill Dmitriev has said.Dr Reddy’s, one of India’s top pharmaceutical companies, will carry out Phase III clinical trials of Sputnik-V in India, RDIF said. Following the news, Dr Reddy’s shares rallied to close 4.18% higher in India on Wednesday.The Indian trials could start as early as next month, Dmitriev told Reuters, adding trial results could be followed soon after by domestic regulatory approval of Sputnik-V for mass use in India. Topics : Russia’s sovereign wealth fund will supply 100 million doses of its potential coronavirus vaccine to Indian drug company Dr Reddy’s Laboratories , the fund said on Wednesday, as Moscow speeds up plans to distribute its shot abroad.The deal for its Sputnik-V vaccine candidate comes after the Russian Direct Investment Fund (RDIF) reached agreements with Indian manufacturers to produce 300 million doses of the shot in India, also a major consumer of Russian oil and arms.The agreement brings the total number of doses Russia has so far announced that it will supply abroad to just over 200 million – half to Latin America and half to India. RDIF has said it has received requests totaling 1 billion doses. India said last week it was considering granting an emergency authorization for a coronavirus vaccine, particularly for the elderly and people in high-risk workplaces.Emergency useRussia was the first country to grant regulatory approval for a novel coronavirus vaccine, and did so before large-scale trials were complete, stirring concern among scientists and doctors about the safety and efficacy of the shot.Several countries are now considering adopting “emergency use authorization” measures that would fast-track approval of a vaccine in a similar way, however.”We expect emergency use authorization for Sputnik-V vaccine in major markets,” Dmitriev said.Results of early-stage clinical trials of the Russian shot, which were published in international medical journal The Lancet earlier this month, showed promise, G V Prasad, co-chairman of Dr Reddy’s, was cited in the RDIF statement as saying.”Sputnik-V vaccine could provide a credible option in our fight against COVID-19 in India,” he said.There was no detail about the price of Sputnik-V, but RDIF has said previously it was not aiming to make a profit, just to cover costs.In a press briefing late on Tuesday, Balram Bhargava, who heads India’s clinical research agency, the Indian Council of Medical Research, said high-level talks between India and Russia around the vaccine had been ongoing.”There is a high-level committee of the government of India for vaccines that is in dialogue with the Russians,” he said, adding Russia had a good track record in vaccine development and the early-stage overseas trials of Sputnik-V had been promising.It was not immediately clear whether those talks had been instrumental in the deal between RDIF and Dr Reddy’s.The agreement comes as India’s coronavirus cases surged past five million on Wednesday, piling pressure on hospitals grappling with unreliable supplies of oxygen that they need to treat tens of thousands of critically ill patients.This is Dr Reddy’s first foray into a coronavirus vaccine. It has struck a licensing deal with Gilead Sciences Inc to make and sell COVID-19 treatment remdesivir in 127 countries, including India; launched its generic version of remdesivir under the brand name Redyx; and has also tied up with Fujifilm Holdings Corp to launch Fujifilm’s anti-flu drug Avigan (favipiravir) in India as a COVID-19 treatment.
Daily Orange: It took until the final game of the regular season for Syracuse to finally beat a ranked opponent. How important was it for them to get that quality win against Louisville?Creme: “Ranked teams” isn’t really necessarily a category, the Top 25 RPI teams would be a category, top 50 RPI, it’s all part of the consideration, it’s all that’s looked at and discussed. So, yes, in general, beating good teams is extremely important. Syracuse — they’d done a lot of winning, they hadn’t a lot of quality winning, but they’ve done a decent job of beating some decent teams all along. AdvertisementThis is placeholder textDO: You have the Orange as a No. 7 seed right now. What’s the range of seeding it could find itself in?CC: I have them as a seven, but they’re actually a natural eight. One of the things that goes into this is that, in terms of bracketing teams, there are all sorts of procedures, rules that have to be followed, and many cases, especially this year, it’s extra tough this year because there are so many host schools in the mix and the Big East makes it tough because there are eight teams from the Big East in the bracket, so there’s very limited movement. So because of that, I had to move Syracuse up from a natural eight up one seed line to a seven. DO: What are the biggest strengths and weaknesses of SU’s resume?CC: They didn’t really lose to any bad teams. They were fairly competitive with Notre Dame at Notre Dame, that’s something to note as well, I think. They don’t have any bad losses, and that’s another thing, too, they didn’t really stumble anywhere. They’d probably like to have the Temple game back, but I’m not going to kill them for that, Temple’s easily their worst loss. If you had to define a hole, Temple would be it. While we talk about versus Top 25 teams and versus top 100 and the last 12 and the strength of schedule, and you talk about all these little metrics, it still comes down to watching games, and if you saw how Syracuse played Notre Dame, and I did catch about half of that game, then you do understand that a team can play or not. You do get a sense just by watching them. That’s a pretty good team. And I think that’s going to be the takeaway for Syracuse. That’s a pretty good team. Comments DO: You project eight teams from the Big East to make the tournament, so how much does the quality of the conference help the Orange?CC: The conference name doesn’t necessarily come into play, it’s each individual team compared to each individual team. That’s one thing I think we — the conference’s are so important in the game that I think we want to apply that. I think you alluded to this, it’s the schedule that they get to play because they’re in a conference, and those are the teams that happen to be in the conference. So that’s the helpful part. The schedule strength gets a little bit better when they get in the Big East because Big East competition happens to be better.” Published on March 17, 2013 at 11:00 pm Contact David: [email protected] | @DBWilson2 Syracuse appears to be headed to its first NCAA Tournament since 2008. The Orange finished third in the Big East and reached the conference tournament semifinals before losing to Connecticut on Monday. The Daily Orange spoke with ESPN bracketologist Charlie Creme about SU’s resume and where it could take it for the first round of the tournament. Facebook Twitter Google+ DO: What are some potential locations we could be looking at for SU?CC: Honestly, it could be just about anywhere that’s not Storrs, wherever Notre Dame’s playing, Queens — essentially as long as they’re not going to conflict with any Big East schools, Syracuse is in a position where they can honestly go anywhere.